Baltimore Washington Financial Advisors Inc. Has $700,000 Stock Position in Eli Lilly and Company $LLY

Baltimore Washington Financial Advisors Inc. raised its position in Eli Lilly and Company (NYSE:LLY) by 5.8% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 898 shares of the company’s stock after acquiring an additional 49 shares during the period. Baltimore Washington Financial Advisors Inc.’s holdings in Eli Lilly and Company were worth $700,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently modified their holdings of LLY. Wealth Preservation Advisors LLC acquired a new position in Eli Lilly and Company during the first quarter worth $27,000. Financial Gravity Companies Inc. bought a new stake in shares of Eli Lilly and Company during the second quarter worth about $31,000. Blume Capital Management Inc. increased its position in shares of Eli Lilly and Company by 46.7% during the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after acquiring an additional 14 shares in the last quarter. IMG Wealth Management Inc. acquired a new stake in shares of Eli Lilly and Company in the 2nd quarter worth about $35,000. Finally, TD Capital Management LLC lifted its position in Eli Lilly and Company by 129.2% in the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after acquiring an additional 31 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. Daiwa America lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. Leerink Partnrs upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Monday, November 10th. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. Wall Street Zen raised shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 1st. Finally, Sanford C. Bernstein upped their target price on shares of Eli Lilly and Company from $1,100.00 to $1,300.00 and gave the stock an “outperform” rating in a research note on Monday. Three research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average target price of $1,047.50.

Eli Lilly and Company Stock Down 0.4%

Eli Lilly and Company stock opened at $1,105.45 on Thursday. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,111.99. The firm has a 50 day moving average price of $876.09 and a 200-day moving average price of $794.85. The company has a market capitalization of $1.05 trillion, a P/E ratio of 72.25, a P/E/G ratio of 1.21 and a beta of 0.43. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. During the same quarter in the previous year, the firm posted $1.18 EPS. Eli Lilly and Company’s revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.